JP2005503356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503356A5 JP2005503356A5 JP2003501989A JP2003501989A JP2005503356A5 JP 2005503356 A5 JP2005503356 A5 JP 2005503356A5 JP 2003501989 A JP2003501989 A JP 2003501989A JP 2003501989 A JP2003501989 A JP 2003501989A JP 2005503356 A5 JP2005503356 A5 JP 2005503356A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- benzodiazepin
- dimethoxy
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 43
- -1 heptynyl Chemical group 0.000 claims 38
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 12
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 10
- 125000001544 thienyl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000005842 heteroatoms Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 4
- 125000004434 sulfur atoms Chemical group 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 150000001350 alkyl halides Chemical class 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 3
- 230000002757 inflammatory Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 230000003213 activating Effects 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 2
- 229910052763 palladium Inorganic materials 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- PUOAETJYKQITMO-FYJGNVAPSA-N (3E)-1-[1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1\C=C(C1=O)/CCCN1C(C)C1=CC=C(F)C=C1 PUOAETJYKQITMO-FYJGNVAPSA-N 0.000 claims 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- ASCRLTIXZKFQJI-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)-7,8-diethoxy-3-ethyl-5H-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2CC(=O)N(CC)N=C1C1=CC2=CC=CC=C2S1 ASCRLTIXZKFQJI-UHFFFAOYSA-N 0.000 claims 1
- SJABLWFWDKABFZ-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)-7,8-diethoxy-5-propyl-3,5-dihydro-2,3-benzodiazepin-4-one Chemical compound N1C(=O)C(CCC)C2=CC(OCC)=C(OCC)C=C2C(C=2SC3=CC=CC=C3C=2)=N1 SJABLWFWDKABFZ-UHFFFAOYSA-N 0.000 claims 1
- OWTKSBICDHTGEY-UHFFFAOYSA-N 1-[4-[3,5-bis(trifluoromethyl)phenyl]phenyl]-7,8-dimethoxy-3-methyl-5H-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OWTKSBICDHTGEY-UHFFFAOYSA-N 0.000 claims 1
- HULIXCDYHMLUNC-UHFFFAOYSA-N 1-benzyl-7,8-diethoxy-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound O=C1CN=C(C=2C=CC=CC=2)C=2C=C(OCC)C(OCC)=CC=2N1CC1=CC=CC=C1 HULIXCDYHMLUNC-UHFFFAOYSA-N 0.000 claims 1
- DBSPEUQZDHURPN-UHFFFAOYSA-N 1-benzyl-7,8-dimethoxy-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound O=C1CN=C(C=2C=CC=CC=2)C=2C=C(OC)C(OC)=CC=2N1CC1=CC=CC=C1 DBSPEUQZDHURPN-UHFFFAOYSA-N 0.000 claims 1
- IQWQEVCQXDEINJ-UHFFFAOYSA-N 1-ethyl-3-[hydroxy(diphenyl)methyl]-7,8-dimethoxy-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 IQWQEVCQXDEINJ-UHFFFAOYSA-N 0.000 claims 1
- HCIKDGRDIWWCHS-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-3-[(2-methoxyphenyl)methyl]-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1OC HCIKDGRDIWWCHS-UHFFFAOYSA-N 0.000 claims 1
- WAXLSETXOXLXDV-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-(4-phenylphenyl)-3H-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C(C=C1)=CC=C1C1=CC=CC=C1 WAXLSETXOXLXDV-UHFFFAOYSA-N 0.000 claims 1
- WNWRPVFIEUZBNY-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-[4-(3-phenylmethoxyprop-1-ynyl)phenyl]-3H-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C(C=C1)=CC=C1C#CCOCC1=CC=CC=C1 WNWRPVFIEUZBNY-UHFFFAOYSA-N 0.000 claims 1
- PKLOQQDQBJEJQS-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-phenyl-3-[(3-phenylphenyl)methyl]-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC(C=1)=CC=CC=1C1=CC=CC=C1 PKLOQQDQBJEJQS-UHFFFAOYSA-N 0.000 claims 1
- DNVLRCDPCFXSAQ-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-phenyl-3-[(4-phenylphenyl)methyl]-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC(C=C1)=CC=C1C1=CC=CC=C1 DNVLRCDPCFXSAQ-UHFFFAOYSA-N 0.000 claims 1
- WQQPGMSAJNSWML-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-phenyl-3-prop-2-ynyl-3H-1,4-benzodiazepin-2-one Chemical compound N=1C(CC#C)C(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 WQQPGMSAJNSWML-UHFFFAOYSA-N 0.000 claims 1
- DPZCMNIHVJZAFB-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 DPZCMNIHVJZAFB-UHFFFAOYSA-N 0.000 claims 1
- DZPJQTYYVVAKCK-UHFFFAOYSA-N 1-ethyl-7-hydroxy-5-phenyl-3,4-dihydro-1,4-benzodiazepine-2,8-dione Chemical compound N1CC(=O)N(CC)C2=CC(=O)C(O)=CC2=C1C1=CC=CC=C1 DZPJQTYYVVAKCK-UHFFFAOYSA-N 0.000 claims 1
- LXWQJQHNSJLQTO-UHFFFAOYSA-N 10-phenyl-2,3,6,8-tetrahydro-[1,4]dioxino[2,3-h][1,4]benzodiazepin-7-one Chemical compound C12=CC=3OCCOC=3C=C2NC(=O)CN=C1C1=CC=CC=C1 LXWQJQHNSJLQTO-UHFFFAOYSA-N 0.000 claims 1
- MAGIXZPMCBHOFV-UHFFFAOYSA-N 2-(1-ethyl-7,8-dimethoxy-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)acetamide Chemical compound N=1C(CC(N)=O)C(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 MAGIXZPMCBHOFV-UHFFFAOYSA-N 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- ZEKZWMAZSZKUMS-UHFFFAOYSA-N 3-(1-benzyl-4-hydroxypiperidin-4-yl)-1-ethyl-7,8-dimethoxy-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1C(CC1)(O)CCN1CC1=CC=CC=C1 ZEKZWMAZSZKUMS-UHFFFAOYSA-N 0.000 claims 1
- XMVVYXKYZQBPRB-UHFFFAOYSA-N 3-[(1-ethyl-7,8-dimethoxy-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)methyl]benzamide Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC(C(N)=O)=C1 XMVVYXKYZQBPRB-UHFFFAOYSA-N 0.000 claims 1
- MBUSWDJSEGOHES-UHFFFAOYSA-N 3-[(8-ethoxy-7-methoxy-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)methyl]benzamide Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OCC)=CC=2N(C)C(=O)C1CC1=CC=CC(C(N)=O)=C1 MBUSWDJSEGOHES-UHFFFAOYSA-N 0.000 claims 1
- FGMBQTNFQLFNRR-UHFFFAOYSA-N 3-[1,2-bis(4-bromophenyl)ethyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1C(C=1C=CC(Br)=CC=1)CC1=CC=C(Br)C=C1 FGMBQTNFQLFNRR-UHFFFAOYSA-N 0.000 claims 1
- USUFZAYMDBWDIX-UHFFFAOYSA-N 3-benzyl-7,8-diethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OCC)C(OCC)=CC=2NC(=O)C1CC1=CC=CC=C1 USUFZAYMDBWDIX-UHFFFAOYSA-N 0.000 claims 1
- RGEJQYAPVPRMKI-UHFFFAOYSA-N 3-benzyl-8-ethoxy-1-ethyl-7-methoxy-5-phenyl-3H-1,4-benzodiazepin-2-one;8-ethoxy-1-ethyl-7-methoxy-3,5-diphenyl-3H-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OCC)=CC=2N(CC)C(=O)C(C=2C=CC=CC=2)N=C1C1=CC=CC=C1.N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OCC)=CC=2N(CC)C(=O)C1CC1=CC=CC=C1 RGEJQYAPVPRMKI-UHFFFAOYSA-N 0.000 claims 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- IXVZTSJPZJXQPY-UHFFFAOYSA-N 5-(1H-indol-5-yl)-7,8-dimethoxy-1-methyl-3H-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=C(NC=C2)C2=C1 IXVZTSJPZJXQPY-UHFFFAOYSA-N 0.000 claims 1
- ZOKLVYBIKSORDC-UHFFFAOYSA-N 5-(2-bromophenyl)-7,8-dimethoxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)CN=C1C1=CC=CC=C1Br ZOKLVYBIKSORDC-UHFFFAOYSA-N 0.000 claims 1
- OUPKYSJIOYLADC-UHFFFAOYSA-N 5-(3-bromophenyl)-7,8-dimethoxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)CN=C1C1=CC=CC(Br)=C1 OUPKYSJIOYLADC-UHFFFAOYSA-N 0.000 claims 1
- NXYWSJCICDUCEQ-UHFFFAOYSA-N 5-(3-bromophenyl)-7,8-dimethoxy-1-methyl-3H-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=CC(Br)=C1 NXYWSJCICDUCEQ-UHFFFAOYSA-N 0.000 claims 1
- YFGFRHZXXKDTFA-UHFFFAOYSA-N 5-(3-chlorophenyl)-7,8-dimethoxy-1-methyl-3H-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=CC(Cl)=C1 YFGFRHZXXKDTFA-UHFFFAOYSA-N 0.000 claims 1
- VGESKMFUGWXWCQ-UHFFFAOYSA-N 5-(4-bromophenyl)-7,8-dimethoxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)CN=C1C1=CC=C(Br)C=C1 VGESKMFUGWXWCQ-UHFFFAOYSA-N 0.000 claims 1
- JAFBIGGLFRQXES-UHFFFAOYSA-N 7,8-diethoxy-1-ethyl-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2N(CC)C(=O)CN=C1C1=CC=CC=C1 JAFBIGGLFRQXES-UHFFFAOYSA-N 0.000 claims 1
- NALNPEFGPDBRCS-UHFFFAOYSA-N 7,8-diethoxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2N(C)C(=O)CN=C1C1=CC=CC=C1 NALNPEFGPDBRCS-UHFFFAOYSA-N 0.000 claims 1
- RBIMGKPHNCHXMS-UHFFFAOYSA-N 7,8-diethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2NC(=O)CN=C1C1=CC=CC=C1 RBIMGKPHNCHXMS-UHFFFAOYSA-N 0.000 claims 1
- JEFSPAVNHMTXPS-UHFFFAOYSA-N 7,8-dimethoxy-1-[4-(4-methoxyphenyl)phenyl]-3-methyl-5H-2,3-benzodiazepin-4-one Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C=2C3=CC(OC)=C(OC)C=C3CC(=O)N(C)N=2)C=C1 JEFSPAVNHMTXPS-UHFFFAOYSA-N 0.000 claims 1
- WRCGPPOUYKGAFN-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-(3-phenylphenyl)-3H-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C(C=1)=CC=CC=1C1=CC=CC=C1 WRCGPPOUYKGAFN-UHFFFAOYSA-N 0.000 claims 1
- XRGUXDBXZXGOMC-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-piperidin-1-yl-3H-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1N1CCCCC1 XRGUXDBXZXGOMC-UHFFFAOYSA-N 0.000 claims 1
- CIBFDTUUNLMFMC-UHFFFAOYSA-N 7,8-dimethoxy-1-phenyl-3,5-dihydro-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)NN=C1C1=CC=CC=C1 CIBFDTUUNLMFMC-UHFFFAOYSA-N 0.000 claims 1
- XLAQCBYTYMNGDR-UHFFFAOYSA-N 7,8-dimethoxy-1-phenyl-3-propyl-5H-2,3-benzodiazepin-4-one Chemical compound C12=CC(OC)=C(OC)C=C2CC(=O)N(CCC)N=C1C1=CC=CC=C1 XLAQCBYTYMNGDR-UHFFFAOYSA-N 0.000 claims 1
- NSFKQWZKLQUICF-UHFFFAOYSA-N 7,8-dimethoxy-3-(2-methylsulfanylethyl)-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one;3-(1H-indol-3-ylmethyl)-7,8-dimethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)C(CCSC)N=C1C1=CC=CC=C1.C1=2C=C(OC)C(OC)=CC=2NC(=O)C(CC=2C3=CC=CC=C3NC=2)N=C1C1=CC=CC=C1 NSFKQWZKLQUICF-UHFFFAOYSA-N 0.000 claims 1
- CBZDWXSMWJWFGA-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-(4-thiophen-2-ylphenyl)-5H-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CS1 CBZDWXSMWJWFGA-UHFFFAOYSA-N 0.000 claims 1
- UJSOHZFFVQFFQG-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-[4-(3-nitrophenyl)phenyl]-5H-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CC([N+]([O-])=O)=C1 UJSOHZFFVQFFQG-UHFFFAOYSA-N 0.000 claims 1
- ACXGWEHMIUPNGX-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-[4-[3-(trifluoromethyl)phenyl]phenyl]-5H-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CC(C(F)(F)F)=C1 ACXGWEHMIUPNGX-UHFFFAOYSA-N 0.000 claims 1
- FVCLLYSNQRDQGL-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)C(C)N=C1C1=CC=CC=C1 FVCLLYSNQRDQGL-UHFFFAOYSA-N 0.000 claims 1
- JPTWVKXRRJCVIB-UHFFFAOYSA-N 7,8-dimethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)CN=C1C1=CC=CC=C1 JPTWVKXRRJCVIB-UHFFFAOYSA-N 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N Lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 claims 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N Monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- IRSNKBQBTFWNAN-UHFFFAOYSA-N ethyl 2-(7,8-diethoxy-2-oxo-5-phenyl-3H-1,4-benzodiazepin-1-yl)acetate Chemical compound N=1CC(=O)N(CC(=O)OCC)C2=CC(OCC)=C(OCC)C=C2C=1C1=CC=CC=C1 IRSNKBQBTFWNAN-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims 1
- 150000002429 hydrazines Chemical class 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000002524 organometallic group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 101710031992 pRL90232 Proteins 0.000 claims 1
- 101710035540 plaa2 Proteins 0.000 claims 1
- 239000001184 potassium carbonate Substances 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- QVCOXWYMPCBIMH-UHFFFAOYSA-N prop-2-ynyl carbamate Chemical compound NC(=O)OCC#C QVCOXWYMPCBIMH-UHFFFAOYSA-N 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Claims (30)
〔式中、
Xは、NR4基を表し、Yは、CR6R6′基を表し、R4、R6およびR6′は、以下に定義され、あるいは
Xは、CR4R4′基を表し、Yは、NR6基を表し、R4、R4′およびR6は、以下に定義されるかのいずれかであり、
Zは、酸素または硫黄原子を表し、
R1は、C1〜C12アルキル、C3〜C6シクロアルキル、C6〜C18アリール、C6〜C18アリールC1〜C4アルキル、C1〜C12アルキルC6〜C18アリール基、1〜3個のヘテロ原子を有する、芳香族もしくは非芳香族のC5〜C18複素環、またはOR2、SR2もしくはNR2R3基であって、(i)R2およびR3は、互いに独立して、水素原子、C1〜C6アルキル、C3〜C6シクロアルキル、C6〜C12アリール基、および1〜3個のヘテロ原子を有する、芳香族もしくは非芳香族のC5〜C12複素環からなる群から選ばれるか、または(ii)R2およびR3は、まとまって、2〜6個の炭素原子を有し、一つ以上の二重結合を含むこともあり、かつ/または酸素、硫黄もしくは窒素原子によって中断されていることもある、直鎖または分岐鎖炭化水素を形成し;
R4およびR4′は、同じであるか、または異なっていて、C3〜C6シクロアルキル、非置換C6〜C18アリール、C6〜C18アリールC1〜C4アルキル、C1〜C12アルキルC6〜C18アリール基、または1〜3個のヘテロ原子を有する、芳香族もしくは非芳香族のC5〜C18複素環を表し、Xが基CR4R4′であるときは、同じであるか、または異なっているR4およびR4′は、水素原子、C1〜C12アルキル、C6〜C18アリール、C2〜C6アルケニル、C2〜C6アルキニル、NO2、CF3、CN、NR′R″、SR′、OR′、COOR′、CONR′R″およびNHCOR′R″基からなる群からも選ばれ、R′およびR″は、互いに独立して、水素原子、C1〜C6アルキル、C1〜C6アルコキシ、C3〜C6シクロアルキル、C6〜C12アリール基、および1〜3個のヘテロ原子を有する、芳香族もしくは非芳香族のC5〜C12複素環からなる群から選ばれ;
R6およびR6′は、同じであるか、または異なっていて、水素原子、C1〜C6アルキル、C6〜C18アリール、C6〜C18アリールC1〜C4アルキル、C1〜C12アルキルC6〜C18アリール、好ましくはフェニル、ベンジル基およびC1〜C6アルキルフェニル基からなる群から選ばれ;
R7およびR8は、互いに独立して、水素原子、C1〜C12アルキル基およびOR2基(R2は、上記に定義される)からなる群から選ばれるか(ただし、R7およびR8が、ともには水素原子を表さない)、またはR7およびR8は、まとまって、2〜6個の炭素原子を有し、一つ以上の二重結合を含むこともあり、かつ/もしくは酸素、硫黄もしくは窒素原子によって中断されていることもある、直鎖もしくは分岐鎖炭化水素を形成し;
上記に定義されたアルキル、アルケニル、アルキニル、アルキルアリール、アラルキル、シクロアルキル、アリール、フェニル、複素環基および炭化水素鎖は、同じであるか、または異なっている一つ以上の、好ましくはハロゲン原子、C1〜C12アルキル、C6〜C18アリール、C2〜C6アルケニル、C2〜C6アルキニル、複素環、OH、=O、NO2、NR′R″、CN、CF3、COR′、COOR′、C1〜C6アルコキシ、ジC1〜C6アルキルアミノ、NHCOR′およびCONR′R″基(R′およびR″は、上記のとおり定義される)からなる群から選ばれる、置換基で置換されていることもある〕
で示される化合物、およびその塩。 Formula (I):
[Where,
X represents an NR 4 group, Y represents a CR 6 R 6 ′ group, R 4 , R 6 and R 6 ′ are defined below, or X represents a CR 4 R 4 ′ group, Y represents an NR 6 group, R 4 , R 4 ′ and R 6 are any of those defined below;
Z represents an oxygen or sulfur atom,
R 1 is C 1 -C 12 alkyl, C 3 -C 6 cycloalkyl, C 6 -C 18 aryl, C 6 -C 18 aryl C 1 -C 4 alkyl, C 1 -C 12 alkyl C 6 -C 18 An aryl group, an aromatic or non-aromatic C 5 -C 18 heterocycle having 1 to 3 heteroatoms, or an OR 2 , SR 2 or NR 2 R 3 group, wherein (i) R 2 and R 3 is independently of each other a hydrogen atom, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 6 -C 12 aryl group, and 1 to 3 heteroatoms, aromatic or non- Selected from the group consisting of aromatic C 5 -C 12 heterocycles, or (ii) R 2 and R 3 collectively have from 2 to 6 carbon atoms and one or more double bonds And / or may be interrupted by oxygen, sulfur or nitrogen atoms Other forms a branched chain hydrocarbons;
R 4 and R 4 ′ are the same or different and are C 3 -C 6 cycloalkyl, unsubstituted C 6 -C 18 aryl, C 6 -C 18 aryl C 1 -C 4 alkyl, C 1 -C having 12 alkyl C 6 -C 18 aryl group, or 1-3 heteroatoms, represents a C 5 -C 18 heterocyclic aromatic or non-aromatic, X is a group CR 4 R 4 ' When R 4 and R 4 ′ which are the same or different are hydrogen atom, C 1 -C 12 alkyl, C 6 -C 18 aryl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl , NO 2 , CF 3 , CN, NR′R ″, SR ′, OR ′, COOR ′, CONR′R ″ and NHCOR′R ″, wherein R ′ and R ″ are independent of each other and a hydrogen atom, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl Alkyl, C 6 -C 12 aryl groups, and having 1-3 heteroatoms, selected from the group consisting of C 5 -C 12 heterocyclic aromatic or non-aromatic;
R 6 and R 6 ′ are the same or different and are each a hydrogen atom, C 1 -C 6 alkyl, C 6 -C 18 aryl, C 6 -C 18 aryl C 1 -C 4 alkyl, C 1 -C 12 alkyl C 6 -C 18 aryl, preferably selected from the group consisting of phenyl, benzyl and C 1 -C 6 alkyl phenyl group;
R 7 and R 8 are independently selected from the group consisting of a hydrogen atom, a C 1 -C 12 alkyl group and an OR 2 group (R 2 is defined above), provided that R 7 and R 8 R 8 does not both represent a hydrogen atom), or R 7 and R 8 together have 2 to 6 carbon atoms, may contain one or more double bonds, and Form linear or branched hydrocarbons which may be interrupted by oxygen, sulfur or nitrogen atoms;
The alkyl, alkenyl, alkynyl, alkylaryl, aralkyl, cycloalkyl, aryl, phenyl, heterocyclic group and hydrocarbon chain defined above are one or more, preferably halogen atoms, which are the same or different. C 1 -C 12 alkyl, C 6 -C 18 aryl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heterocycle, OH, ═O, NO 2 , NR′R ″, CN, CF 3 , COR ', COOR', C 1 ~C 6 alkoxy, di C 1 -C 6 alkylamino, NHCOR 'and CONR'R "group (R' and R" are defined as above) selected from the group consisting of Or may be substituted with a substituent.
And a salt thereof.
(a)一つ以上のハロゲン原子、特に塩素、臭素またはヨウ素、好ましくは塩素で、または
(b)一つ以上のOR′基、特にメトキシまたはエトキシで、または
(c)COR′基、特にアセチルで、または
(d)トリフルオロメチル基で、または
(e)アルキルもしくはアルキニル基、たとえばヘプチニルで、または
(f)それ自体が、好ましくは基(a)〜(e)のうちから選ばれる、一つ以上の基で置換されていることもある、アリール基もしくは複素環、特にフェニル、フリル、ピリジルまたはチエニル基
で置換されたフェニル基である、請求項13記載の化合物。 R 1 is a phenyl group, in particular a substituted phenyl, preferably (a) one or more halogen atoms, in particular chlorine, bromine or iodine, preferably chlorine, or (b) one or more OR ′ groups, in particular methoxy or Preferably in ethoxy, or (c) a COR ′ group, in particular acetyl, or (d) a trifluoromethyl group, or (e) an alkyl or alkynyl group, such as heptynyl, or (f) itself preferably a group a) to (e), which may be substituted with one or more groups, aryl groups or heterocycles, in particular phenyl groups substituted with phenyl, furyl, pyridyl or thienyl groups, 14. A compound according to claim 13.
7,8−ジメトキシ−1−(2−ナフチル)−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(4−クロロフェニル)−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(2−ベンゾ〔b〕チエニル)−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−〔4−(2−フリル)フェニル〕−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(2−ベンゾ〔b〕チエニル)−7,8−ジエトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(2−ベンゾ〔b〕チエニル)−7,8−ジエトキシ−5−エチル−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(4−クロロフェニル)−7,8−ジエトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
5−(4−クロロフェニル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−フェニル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(2−ベンゾ〔b〕チエニル)−7,8−ジエトキシ−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(2−ベンゾ〔b〕チエニル)−7,8−ジエトキシ−5−n−プロピル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−3−メチル−1−(1−ナフチル)−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
3−ベンジル−7,8−ジメトキシ−1−フェニル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
3−ドデシル−7,8−ジメトキシ−1−フェニル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−3−(12−メトキシ−12−オキソドデシル)−1−フェニル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
3−エチル−7,8−ジメトキシ−1−フェニル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−1−フェニル−3−n−プロピル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(4−ヨードフェニル)−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−1−〔4−(2−メトキシフェニル)フェニル〕−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−1−〔4−(3−メトキシフェニル)フェニル〕−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−〔4−(3−アセチルフェニル)フェニル〕−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−3−メチル−1−〔4−(3−ピリジル)フェニル〕−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−〔4−(4−アセチルフェニル)フェニル〕−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−〔4−(3−アセトアミドフェニル)フェニル〕−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(4−ブロモフェニル)−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−1−〔4−(4−メトキシフェニル)フェニル〕−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−〔4−〔3−(トリフルオロメチル)フェニル〕フェニル〕−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−3−メチル−1−〔4−(2−メチルフェニル)フェニル〕−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−3−メチル−1−〔4−(3−メチルフェニル)フェニル〕−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−3−メチル−1−〔4−(4−メチルフェニル)フェニル〕−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−〔4−(4−クロロフェニル)フェニル〕−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−3−メチル−1−〔4−(2−チエニル)フェニル〕−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−{4−〔3,5−ビス−(トリフルオロメチル)フェニル〕フェニル}−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−〔4−(ヘプチン−1−イル)フェニル〕−7,8−ジメトキシ−3−メチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−3−メチル−1−〔4−(3−ニトロフェニル)フェニル〕−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(2−ベンゾ〔b〕チエニル)−7,8−ジエトキシ−3−エチル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
1−(2−ベンゾ〔b〕チエニル)−7,8−ジエトキシ−3−メチル−5−n−プロピル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
3,5−ジベンジル−7,8−ジメトキシ−1−フェニル−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−1−フェニル−3−(3−ヒドロキシプロピル)−3,5−ジヒドロ−4H−2,3−ベンゾジアゼピン−4−オン
7,8−ジメトキシ−1−メチル−5−フェニル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−5−(3,4−ジメトキシフェニル)−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
5−(2−ベンゾ〔b〕チエニル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
5−(3−クロロフェニル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
5−(2−ベンゾ〔b〕フリル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
5−(2−フリル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
5−(4−アセチルフェニル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−メチル−5−(2−チエニル)−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−5−(3−メトキシフェニル)−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−5−(2−メトキシフェニル)−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
5−(5−インドリル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
5−(6−ベンジルオキシ−2−ナフチル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−5−(6−メトキシ−2−ナフチル)−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
5−(2−インドリル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−メチル−5−(ピペリジン−1−イル)−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−メチル−5−(2−メチルフェニル)−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−5−(4−メトキシフェニル)−1−メチル−1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−オン
5−(1,1′−ビフェニル−3−イル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
5−(4−ブロモフェニル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
5−(4−ブロモフェニル)−7,8−ジメトキシ−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
8−ブロモ−5−(4−ブロモフェニル)−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7−ヨード−5−〔3−(トリフルオロメチル)フェニル〕−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7−メトキシ−5−〔3−(トリフルオロメチル)フェニル〕−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−ベンジル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジエトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−5−フェニル−1−プロピル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジエトキシ−1−メチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジエトキシ−1−エチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
エチル (7,8−ジエトキシ−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−1−イル)アセテート
10−フェニル−2,3,6,8−テトラヒドロ−7H−〔1,4〕ジオキシノ〔2,3−h〕〔1,4〕ベンゾジアゼピン−7−オン
1−ベンジル−7,8−ジエトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジエトキシ−3−メチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−ベンジル−7,8−ジエトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−エチル−7,8−ジヒドロキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
5−(4−ブロモフェニル)−1−エチル−7,8−ジメトキシ−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
5−(3−ブロモフェニル)−7,8−ジメトキシ−1−メチル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
5−(3−ブロモフェニル)−7,8−ジメトキシ−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
5−(3−ブロモフェニル)−1−エチル−7,8−ジメトキシ−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
5−{4−〔3−(ベンジルオキシ)プロパ−1−イニル〕フェニル}−1−エチル−7,8−ジメトキシ−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
tert−ブチル 3−〔4−(1−エチル−7,8−ジメトキシ−2−オキソ−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−5−イル)フェニル〕プロパ−2−イニルカルバメート
5−(1,1′−ビフェニル−4−イル)−1−エチル−7,8−ジメトキシ−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(4−クロロベンジル)−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−エチル−7,8−ジメトキシ−5−〔4−(フェニルエチニル)フェニル〕−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−アリル−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−エチル−7,8−ジメトキシ−5−フェニル−3−プロパ−2−イニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−エチル−7,8−ジメトキシ−5−〔4−(2−フェニルエチル)フェニル〕−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
エチル (1−エチル−7,8−ジメトキシ−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)アセテート
1−エチル−7,8−ジメトキシ−5−〔3−(フェニルエチニル)フェニル〕−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
5−(2−ブロモフェニル)−7,8−ジメトキシ−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
(1−エチル−7,8−ジメトキシ−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)アセトニトリル
3−(2−ブロモベンジル)−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(4−ブロモベンジル)−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−〔(3−ブロモフェニル)(ヒドロキシ)メチル〕−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(3−ブロモベンジル)−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(1,1′−ビフェニル−4−イルメチル)−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(1−ベンジル−4−ヒドロキシピペリジン−4−イル)−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(4−クロロベンジル)−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−〔(1−エチル−7,8−ジメトキシ−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)メチル〕ベンゾニトリル
3−ベンジル−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−エチル−7,8−ジメトキシ−3−(2−メトキシベンジル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−〔(1−エチル−7,8−ジメトキシ−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)メチル〕ベンズアミド
3−〔3−(アミノメチル)ベンジル〕−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(1,1′−ビフェニル−3−イルメチル)−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−ベンジル−7,8−ジエトキシ−1−エチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
2−(1−エチル−7,8−ジメトキシ−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)アセトアミド
3−(2−クロロベンジル)−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−エチル−7,8−ジメトキシ−3−(2−メチルベンジル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
8−エトキシ−7−メトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
8−エトキシ−7−メトキシ−1−メチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−エチル−7,8−ジメトキシ−5−フェニル−3−〔3−(トリフルオロメチル)ベンジル〕−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−エチル−7,8−ジメトキシ−3−(3−メトキシベンジル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
1−エチル−7,8−ジメトキシ−3−(4−メチルベンジル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−〔1,2−ビス(4−ブロモフェニル)エチル〕−1−エチル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−〔(8−エトキシ−7−メトキシ−1−メチル−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)メチル〕ベンゾニトリル
2−〔(8−エトキシ−7−メトキシ−1−メチル−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)メチル〕ベンゾニトリル
3−〔(8−エトキシ−7−メトキシ−1−メチル−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)メチル〕ベンズアミド
8−メトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7−メトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7−メトキシ−1−メチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
8−メトキシ−1−メチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−5−(4−フルオロフェニル)−1−メチル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−メチル−5−(4−ピリジル)−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−メチル−5−(3,5−ビス−トリフルオロメチルフェニル)−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−5−(4−N,N−ジメチルアミノフェニル)−1−メチル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−メチル−5−〔(E)−2−フェニルエテニル〕−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−メチル−5−(2−フェニルエチニル)−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−メチル−5−(N−テトラヒドロ−1,2,3,4−イソキノリル)−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−3−イソブチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−ベンジル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−3−メチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−3−(1H−イミダゾール−4−イルメチル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−3−(1H−インドール−3−イルメチル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−3−(2−メチルチオエチル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
(S)−3−ベンジル−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
(S)−3−ベンジル−7,8−ジメトキシ−1−メチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−メチル−5−(2−フェニルエチル)−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
(7,8−ジメトキシ−5−フェニル−2−オキソ−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)ベンジル(S)−ブチルカルバメート
(S)−3−(4−アミノブチル)−7,8−ジメトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
(S)−N−〔4−(7,8−ジメトキシ−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)ブチル〕アセトアミド
N−〔4−(7,8−ジメトキシ−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)ブチル〕グアニジニウム (S)−ビス トリフルオロアセテート
7,8−ジメトキシ−1−エチル−3−(2−ニトロベンジル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(3,5−ジブロモベンジル)−7,8−ジメトキシ−1−エチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−3−(ジフェニルヒドロキシメチル)−1−エチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−エチル−3−(E−3−フェニルプロペン−2−イル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−エチル−3−(2−アミノベンジル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
7,8−ジメトキシ−1−(2−ヒドロキシエチル)−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(2−シアノベンジル)−7,8−ジメトキシ−1−エチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
N−〔2−(7,8−ジメトキシ−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)ベンジル〕アセトアミド
3−(2−アミノメチルベンジル)−7,8−ジメトキシ−1−エチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
〔(7,8−ジメトキシ−1−エチル−2−オキソ−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)ベンズ−2−イル〕カルボキサミド
N−〔2−(7,8−ジメトキシ−2−オキソ−5−フェニル−2,3−ジヒドロ−1H−1,4−ベンゾジアゼピン−3−イル)ベンジル〕メチルアセトアミド
7,8−ジメトキシ−3,5−ジフェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(2,4−ジクロロベンジル)−7,8−ジメトキシ−1−エチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−(2,5−ジクロロベンジル)−7,8−ジメトキシ−1−エチル−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3,5−ジフェニル−8−エトキシ−7−メトキシ−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−ベンジル−8−エトキシ−7−メトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3−ベンジル−8−エトキシ−1−エチル−7−メトキシ−5−フェニル−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
3,5−ジフェニル−8−エトキシ−1−エチル−7−メトキシ−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
5−フェニル−7−エトキシ−8−メトキシ−1,3−ジヒドロ−2H−1,4−ベンゾジアゼピン−2−オン
のうちから選ばれる、請求項1記載の化合物、およびその塩。 The following compounds:
7,8-Dimethoxy-1- (2-naphthyl) -3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- (4-chlorophenyl) -7,8-dimethoxy-3 -Methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- (2-benzo [b] thienyl) -7,8-dimethoxy-3-methyl-3,5-dihydro-4H- 2,3-benzodiazepin-4-one 1- [4- (2-furyl) phenyl] -7,8-dimethoxy-3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1 -(2-Benzo [b] thienyl) -7,8-diethoxy-3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- (2-benzo [b] thienyl)- 7,8-diethoxy-5-ethi -3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- (4-chlorophenyl) -7,8-diethoxy-3-methyl-3,5-dihydro-4H-2, 3-Benzodiazepin-4-one 5- (4-chlorophenyl) -7,8-dimethoxy-1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one 7,8-dimethoxy-1-phenyl- 3,5-dihydro-4H-2,3-benzodiazepine-4-one 1- (2-benzo [b] thienyl) -7,8-diethoxy-3,5-dihydro-4H-2,3-benzodiazepine-4 1- (2-benzo [b] thienyl) -7,8-diethoxy-5-n-propyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 7,8-dimethoxy-3 -Mechi -1- (1-naphthyl) -3,5-dihydro-4H-2,3-benzodiazepin-4-one 3-benzyl-7,8-dimethoxy-1-phenyl-3,5-dihydro-4H-2, 3-Benzodiazepin-4-one 3-dodecyl-7,8-dimethoxy-1-phenyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 7,8-dimethoxy-3- (12-methoxy -12-oxododecyl) -1-phenyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 3-ethyl-7,8-dimethoxy-1-phenyl-3,5-dihydro-4H- 2,3-Benzodiazepin-4-one 7,8-dimethoxy-1-phenyl-3-n-propyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- (4-iodofe Nyl) -7,8-dimethoxy-3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 7,8-dimethoxy-1- [4- (2-methoxyphenyl) phenyl]- 3-Methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 7,8-dimethoxy-1- [4- (3-methoxyphenyl) phenyl] -3-methyl-3,5-dihydro -4H-2,3-benzodiazepine-4-one 1- [4- (3-acetylphenyl) phenyl] -7,8-dimethoxy-3-methyl-3,5-dihydro-4H-2,3-benzodiazepine 4-one 7,8-dimethoxy-3-methyl-1- [4- (3-pyridyl) phenyl] -3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- [4- (4 -Acetylphenyl Phenyl] -7,8-dimethoxy-3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- [4- (3-acetamidophenyl) phenyl] -7,8-dimethoxy- 3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- (4-bromophenyl) -7,8-dimethoxy-3-methyl-3,5-dihydro-4H-2, 3-Benzodiazepin-4-one 7,8-dimethoxy-1- [4- (4-methoxyphenyl) phenyl] -3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- [4- [3- (trifluoromethyl) phenyl] phenyl] -7,8-dimethoxy-3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one
7,8-Dimethoxy-3-methyl-1- [4- (2-methylphenyl) phenyl] -3,5-dihydro-4H-2,3-benzodiazepin-4-one 7,8-dimethoxy-3-methyl -1- [4- (3-Methylphenyl) phenyl] -3,5-dihydro-4H-2,3-benzodiazepin-4-one 7,8-dimethoxy-3-methyl-1- [4- (4- Methylphenyl) phenyl] -3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- [4- (4-chlorophenyl) phenyl] -7,8-dimethoxy-3-methyl-3,5- Dihydro-4H-2,3-benzodiazepin-4-one 7,8-dimethoxy-3-methyl-1- [4- (2-thienyl) phenyl] -3,5-dihydro-4H-2,3-benzodiazepine 4-on 1 {4- [3,5-bis- (trifluoromethyl) phenyl] phenyl} -7,8-dimethoxy-3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- [ 4- (Heptin-1-yl) phenyl] -7,8-dimethoxy-3-methyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 7,8-dimethoxy-3-methyl-1 -[4- (3-Nitrophenyl) phenyl] -3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- (2-benzo [b] thienyl) -7,8-diethoxy-3- Ethyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 1- (2-benzo [b] thienyl) -7,8-diethoxy-3-methyl-5-n-propyl-3,5 -Dihydro-4H-2,3- Nzodiazepin-4-one 3,5-dibenzyl-7,8-dimethoxy-1-phenyl-3,5-dihydro-4H-2,3-benzodiazepin-4-one 7,8-dimethoxy-1-phenyl-3- (3-hydroxypropyl) -3,5-dihydro-4H-2,3-benzodiazepin-4-one 7,8-dimethoxy-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepine- 2-one 7,8-dimethoxy-5- (3,4-dimethoxyphenyl) -1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one 5- (2-benzo [b] thienyl) -7,8-dimethoxy-1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one 5- (3-chlorophenyl) -7,8-dimethoxy-1-methyl-1,3-di Hydro-1,4-benzodiazepin-2-one 5- (2-benzo [b] furyl) -7,8-dimethoxy-1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one 5- (2-Furyl) -7,8-dimethoxy-1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one 5- (4-acetylphenyl) -7,8-dimethoxy-1-methyl- 1,3-dihydro-1,4-benzodiazepin-2-one 7,8-dimethoxy-1-methyl-5- (2-thienyl) -1,3-dihydro-1,4-benzodiazepin-2-one 7, 8-Dimethoxy-5- (3-methoxyphenyl) -1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one 7,8-dimethoxy-5- (2-methoxyphenyl) -1-methyl -1,3- Hydro-1,4-benzodiazepin-2-one 5- (5-indolyl) -7,8-dimethoxy-1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one 5- (6-benzyl) Oxy-2-naphthyl) -7,8-dimethoxy-1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one 7,8-dimethoxy-5- (6-methoxy-2-naphthyl)- 1-methyl-1,3-dihydro-1,4-benzodiazepin-2-one 5- (2-indolyl) -7,8-dimethoxy-1-methyl-1,3-dihydro-1,4-benzodiazepine-2 -One 7,8-dimethoxy-1-methyl-5- (piperidin-1-yl) -1,3-dihydro-1,4-benzodiazepin-2-one 7,8-dimethoxy-1-methyl-5- ( 2-methyl Phenyl) -1,3-dihydro-1,4-benzodiazepin-2-one 7,8-dimethoxy-5- (4-methoxyphenyl) -1-methyl-1,3-dihydro-1,4-benzodiazepine-2 -On 5- (1,1'-biphenyl-3-yl) -7,8-dimethoxy-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 5- (4-bromo Phenyl) -7,8-dimethoxy-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 5- (4-bromophenyl) -7,8-dimethoxy-1,3-dihydro -2H-1,4-benzodiazepin-2-one 8-bromo-5- (4-bromophenyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one 7-iodo-5- [3 -(Trifluoro Methyl) phenyl] -1,3-dihydro-2H-1,4-benzodiazepin-2-one 7-methoxy-5- [3- (trifluoromethyl) phenyl] -1,3-dihydro-2H-1,4 -Benzodiazepin-2-one 7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 1-benzyl-7,8-dimethoxy-5-phenyl-1,3 -Dihydro-2H-1,4-benzodiazepin-2-one 7,8-diethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 1-ethyl-7,8-dimethoxy -5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-5-phenyl-1-propyl-1,3-dihydro-2H-1,4 Benzodiazepin-2-one 7,8-diethoxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-diethoxy-1-ethyl-5-phenyl- 1,3-dihydro-2H-1,4-benzodiazepin-2-one ethyl (7,8-diethoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-1-yl) Acetate 10-phenyl-2,3,6,8-tetrahydro-7H- [1,4] dioxino [2,3-h] [1,4] benzodiazepin-7-one 1-benzyl-7,8-diethoxy- 5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-diethoxy-3-methyl-5-phenyl-1,3-dihydro-2H-1,4- Nzodiazepin-2-one 3-benzyl-7,8-diethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 1-ethyl-7,8-dihydroxy-5-phenyl- 1,3-dihydro-2H-1,4-benzodiazepin-2-one 5- (4-bromophenyl) -1-ethyl-7,8-dimethoxy-1,3-dihydro-2H-1,4-benzodiazepine- 2-one 5- (3-bromophenyl) -7,8-dimethoxy-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 5- (3-bromophenyl) -7, 8-Dimethoxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one 5- (3-bromophenyl) -1-ethyl-7,8-dimethoxy-1,3-dihydro-2H-1 4-Benzodiazepin-2-one 5- {4- [3- (benzyloxy) prop-1-ynyl] phenyl} -1-ethyl-7,8-dimethoxy-1,3-dihydro-2H-1,4- Benzodiazepin-2-one
tert-butyl 3- [4- (1-ethyl-7,8-dimethoxy-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-5-yl) phenyl] prop-2-ynylcarbamate 5- (1,1′-biphenyl-4-yl) -1-ethyl-7,8-dimethoxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3- (4-chlorobenzyl) -1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 1-ethyl-7,8-dimethoxy-5- [4- (phenylethynyl) ) Phenyl] -1,3-dihydro-2H-1,4-benzodiazepin-2-one 3-allyl-1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4 -Benzodiazepi 2-one 1-ethyl-7,8-dimethoxy-5-phenyl-3-prop-2-ynyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 1-ethyl-7,8 -Dimethoxy-5- [4- (2-phenylethyl) phenyl] -1,3-dihydro-2H-1,4-benzodiazepin-2-oneethyl (1-ethyl-7,8-dimethoxy-2-oxo-5 -Phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) acetate 1-ethyl-7,8-dimethoxy-5- [3- (phenylethynyl) phenyl] -1,3-dihydro- 2H-1,4-benzodiazepin-2-one 5- (2-bromophenyl) -7,8-dimethoxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one (1-ethyl-7, -Dimethoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) acetonitrile 3- (2-bromobenzyl) -1-ethyl-7,8-dimethoxy-5 -Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3- (4-bromobenzyl) -1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H -1,4-benzodiazepin-2-one 3-[(3-bromophenyl) (hydroxy) methyl] -1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4 -Benzodiazepin-2-one 3- (3-bromobenzyl) -1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3- (1,1′-biphenyl-4-ylmethyl) -1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3- (1 -Benzyl-4-hydroxypiperidin-4-yl) -1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3- (4-chloro (Benzyl) -1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3-[(1-ethyl-7,8-dimethoxy-2- Oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) methyl] benzonitrile 3-benzyl-1-ethyl-7,8-dimethoxy-5-phenyl-1,3- Jihyd -2H-1,4-benzodiazepin-2-one 1-ethyl-7,8-dimethoxy-3- (2-methoxybenzyl) -5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2 -On 3-[(1-ethyl-7,8-dimethoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) methyl] benzamide 3- [3- (Aminomethyl) benzyl] -1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3- (1,1′-biphenyl-3- Ylmethyl) -1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3-benzyl-7,8-diethoxy-1-ethyl-5 Enyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 2- (1-ethyl-7,8-dimethoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1, 4-Benzodiazepin-3-yl) acetamide 3- (2-chlorobenzyl) -1-ethyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 1 -Ethyl-7,8-dimethoxy-3- (2-methylbenzyl) -5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 8-ethoxy-7-methoxy-5-phenyl -1,3-dihydro-2H-1,4-benzodiazepin-2-one 8-ethoxy-7-methoxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepi N-2-one 1-ethyl-7,8-dimethoxy-5-phenyl-3- [3- (trifluoromethyl) benzyl] -1,3-dihydro-2H-1,4-benzodiazepin-2-one 1 -Ethyl-7,8-dimethoxy-3- (3-methoxybenzyl) -5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 1-ethyl-7,8-dimethoxy-3 -(4-Methylbenzyl) -5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3- [1,2-bis (4-bromophenyl) ethyl] -1-ethyl- 7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3-[(8-ethoxy-7-methoxy-1-methyl-2-oxo-5-phenyl -2,3-Dighi B-1H-1,4-benzodiazepin-3-yl) methyl] benzonitrile 2-[(8-ethoxy-7-methoxy-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H- 1,4-benzodiazepin-3-yl) methyl] benzonitrile 3-[(8-ethoxy-7-methoxy-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4- Benzodiazepin-3-yl) methyl] benzamide 8-methoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7-methoxy-5-phenyl-1,3-dihydro-2H- 1,4-benzodiazepin-2-one 7-methoxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 8-methoxy-1 Methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-5- (4-fluorophenyl) -1-methyl-1,3-dihydro-2H- 1,4-benzodiazepin-2-one 7,8-dimethoxy-1-methyl-5- (4-pyridyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy- 1-methyl-5- (3,5-bis-trifluoromethylphenyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-5- (4-N, N -Dimethylaminophenyl) -1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-1-methyl-5-[(E) -2-phenylethenyl] -1,3-Di Hydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-1-methyl-5- (2-phenylethynyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one 7 , 8-Dimethoxy-1-methyl-5- (N-tetrahydro-1,2,3,4-isoquinolyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy- 3-isobutyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3-benzyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4 -Benzodiazepin-2-one 7,8-dimethoxy-3-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-3- (1H-i Dazol-4-ylmethyl) -5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-3- (1H-indol-3-ylmethyl) -5-phenyl- 1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-3- (2-methylthioethyl) -5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine 2-one (S) -3-benzyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (S) -3-benzyl-7,8- Dimethoxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-1-methyl-5- (2-phenylethyl) -1,3- Hydro-2H-1,4-benzodiazepin-2-one (7,8-dimethoxy-5-phenyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) benzyl (S) -Butylcarbamate (S) -3- (4-aminobutyl) -7,8-dimethoxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (S) -N- [ 4- (7,8-dimethoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) butyl] acetamide N- [4- (7,8-dimethoxy- 2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) butyl] guanidinium (S) -bis trifluoroacetate 7,8-dimethoxy-1-eth -3- (2-nitrobenzyl) -5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3- (3,5-dibromobenzyl) -7,8-dimethoxy-1- Ethyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-3- (diphenylhydroxymethyl) -1-ethyl-5-phenyl-1,3-dihydro -2H-1,4-benzodiazepin-2-one 7,8-dimethoxy-1-ethyl-3- (E-3-phenylpropen-2-yl) -5-phenyl-1,3-dihydro-2H-1 , 4-Benzodiazepin-2-one 7,8-dimethoxy-1-ethyl-3- (2-aminobenzyl) -5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 7, -Dimethoxy-1- (2-hydroxyethyl) -5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3- (2-cyanobenzyl) -7,8-dimethoxy-1- Ethyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one N- [2- (7,8-dimethoxy-2-oxo-5-phenyl-2,3-dihydro-1H -1,4-benzodiazepin-3-yl) benzyl] acetamide 3- (2-aminomethylbenzyl) -7,8-dimethoxy-1-ethyl-5-phenyl-1,3-dihydro-2H-1,4- Benzodiazepin-2-one [(7,8-dimethoxy-1-ethyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) benz-2-yl] carboxamide N- [2- (7,8-dimethoxy-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl) benzyl] methylacetamide 7,8-dimethoxy-3, 5-Diphenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3- (2,4-dichlorobenzyl) -7,8-dimethoxy-1-ethyl-5-phenyl-1,3- Dihydro-2H-1,4-benzodiazepin-2-one 3- (2,5-dichlorobenzyl) -7,8-dimethoxy-1-ethyl-5-phenyl-1,3-dihydro-2H-1,4- Benzodiazepin-2-one 3,5-diphenyl-8-ethoxy-7-methoxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3-benzyl-8-ethoxy-7-methoxy 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 3-benzyl-8-ethoxy-1-ethyl-7-methoxy-5-phenyl-1,3-dihydro-2H-1 , 4-Benzodiazepin-2-one 3,5-diphenyl-8-ethoxy-1-ethyl-7-methoxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one 5-phenyl-7-ethoxy The compound according to claim 1, which is selected from -8-methoxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one, and a salt thereof.
〔式中、R1、R6、R6′、R7およびR8は、請求項1のとおりに定義される〕
で表される化合物を、炭酸カリウムの存在下で、ハロゲン化アルキルと室温で反応させることによって製造する方法。 The compound of claim 3, wherein Z is an oxygen atom, is represented by formula (VI):
[Wherein R 1 , R 6 , R 6 ′, R 7 and R 8 are defined as in claim 1]
Is produced by reacting an alkyl halide with an alkyl halide in the presence of potassium carbonate at room temperature.
(a)一般式(IV):
〔式中、R6、R6′、R7およびR8は、請求項1のとおりに定義される〕
で表される化合物を、式R1COを有するアシル基を含む化合物と反応させて、式(V):
〔式中、R1、R6、R6′、R7およびR8は、上記のとおりに定義される〕
で表される化合物を得る工程と;
(b)式(V)で表される化合物を、ヒドラジンと反応させて、R1、R6、R6′、R7およびR8が上記のとおりに定義された、式(VI)で表される化合物を得る工程
を含む方法によって得る、請求項24記載の方法。 The compound represented by the general formula (VI) is converted into the following steps:
(A) General formula (IV):
Wherein R 6 , R 6 ′, R 7 and R 8 are defined as in claim 1
Is reacted with a compound containing an acyl group having the formula R 1 CO to give a compound of formula (V):
[Wherein R 1 , R 6 , R 6 ′, R 7 and R 8 are defined as above]
Obtaining a compound represented by:
(B) A compound represented by formula (V) is reacted with hydrazine, and R 1 , R 6 , R 6 ′, R 7 and R 8 are defined as above and represented by formula (VI) 25. A method according to claim 24 obtained by a method comprising the step of obtaining a compound to be prepared.
〔式中、R4、R6、R6′、R7およびR8は、請求項1のとおりに定義され、Gは、活性化基、たとえばハロゲンまたはO−トリフレート基である〕
で表される化合物から、ボロン酸、d′−アルシン−1−イル酸もしくはエステル、または有機亜鉛化合物もしくは有機スズ化合物のような、有機金属酸もしくはエステルの存在下でのパラジウムカップリング反応によって製造する方法。 The compound according to claim 3, wherein Z is an oxygen atom, represented by the general formula (XIV):
Wherein R 4 , R 6 , R 6 ′, R 7 and R 8 are defined as in claim 1 and G is an activating group such as a halogen or O-triflate group.
By a palladium coupling reaction in the presence of an organometallic acid or ester, such as a boronic acid, d'-arsine-1-yl acid or ester, or an organozinc or organotin compound how to.
〔式中、R4、R4′、R6、R7およびR8は、請求項1のとおりに定義され、Gは、ハロゲンのような活性化基である〕
で表される化合物を、パラジウム触媒の存在下で基R1の酸化合物と反応させることによって製造する方法。 The compound according to claim 2, wherein Z is an oxygen atom, the compound represented by the general formula (XVIII):
Wherein R 4 , R 4 ′, R 6 , R 7 and R 8 are defined as in claim 1 and G is an activating group such as halogen.
Method for producing a compound represented by the presence of a palladium catalyst by reacting with an acid compound of group R 1.
〔式中、R1、R4、R4′、R7およびR8は、請求項1のとおりに定義される〕
で表される化合物を、好ましくは溶媒中で、塩基の存在下、ハロゲン化アルキルと好ましくは室温で反応させることによって製造する方法。 The compound according to claim 2, wherein Z is an oxygen atom, the compound represented by the general formula (XXII):
Wherein R 1 , R 4 , R 4 ′, R 7 and R 8 are defined as in claim 1
Wherein the compound is preferably reacted in a solvent in the presence of a base with an alkyl halide, preferably at room temperature.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0107458 | 2001-06-07 | ||
PCT/FR2002/001952 WO2002098865A2 (en) | 2001-06-07 | 2002-06-07 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005503356A JP2005503356A (en) | 2005-02-03 |
JP2005503356A5 true JP2005503356A5 (en) | 2006-01-05 |
Family
ID=8864056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003501989A Pending JP2005503356A (en) | 2001-06-07 | 2002-06-07 | Cyclic nucleotide phosphodiesterase inhibitors, their production and use |
Country Status (9)
Country | Link |
---|---|
US (1) | US7250410B2 (en) |
EP (1) | EP1392663A2 (en) |
JP (1) | JP2005503356A (en) |
AU (2) | AU2002317910B2 (en) |
CA (1) | CA2446696A1 (en) |
IL (2) | IL159105A0 (en) |
NZ (1) | NZ529582A (en) |
WO (1) | WO2002098865A2 (en) |
ZA (1) | ZA200400057B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7125866B1 (en) * | 1999-04-30 | 2006-10-24 | Regents Of The University Of Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
US20060025388A1 (en) * | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20030119029A1 (en) * | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
US7572788B2 (en) * | 1999-04-30 | 2009-08-11 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
AU2003265398A1 (en) | 2002-08-09 | 2004-02-25 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
ATE412415T1 (en) * | 2002-10-30 | 2008-11-15 | Via Pharmaceuticals Inc | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, HAVING A BENZODIAZEPIN STRUCTURE, AND THEIR USE IN THERAPY |
FR2846653B1 (en) * | 2002-10-30 | 2007-04-20 | Neuro3D | INHIBITORS OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, PREPARATION AND USES |
US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2005014534A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
EP1548011A1 (en) * | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20090275099A1 (en) * | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
FR2870539B1 (en) * | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | NEW METHODS AND MEDICINES |
CA2577060A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
US20060052369A1 (en) * | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20070043033A1 (en) * | 2005-06-01 | 2007-02-22 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
US20070105844A1 (en) * | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
EP2604269B1 (en) | 2005-11-01 | 2014-09-24 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones with therapeutic properties |
US7759338B2 (en) * | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
NZ573452A (en) | 2006-06-09 | 2011-09-30 | Univ Michigan | Compositions and methods relating to novel compounds and targets thereof |
NZ579507A (en) * | 2007-03-09 | 2011-11-25 | Univ Michigan | Compositions and methods relating to novel compounds and targets thereof |
JP2010526825A (en) * | 2007-05-10 | 2010-08-05 | エーエムアール テクノロジー インコーポレイテッド | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and their use to block reuptake of norepinephrine, dopamine and serotonin |
AU2008298870C1 (en) * | 2007-09-14 | 2014-10-09 | The Regents Of The University Of Michigan | F1F0-ATPase inhibitors and related methods |
WO2009037302A1 (en) * | 2007-09-18 | 2009-03-26 | Via Pharmaceuticals, Inc. | 5-substituted-1, 4-benz0diazepines as phosphodiesterase inhibitors |
CN101918375A (en) | 2007-11-06 | 2010-12-15 | 密歇根大学董事会 | Benzodiazepinone compounds useful in the treatment of skin conditions |
US8497307B2 (en) | 2008-09-11 | 2013-07-30 | The Regents Of The University Of Michigan | Aryl guanidine F1F0-ATPase inhibitors and related methods |
WO2010121164A2 (en) | 2009-04-17 | 2010-10-21 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
EP2470020A4 (en) | 2009-09-18 | 2013-03-13 | Univ Michigan | Benzodiazepinone compounds and methods of treatment using same |
JP5856063B2 (en) | 2009-11-17 | 2016-02-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 1,4-Benzodiazepine-2,5-dione and related compounds having therapeutic properties |
CN102753544A (en) | 2009-11-17 | 2012-10-24 | 密执安大学评议会 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
AR084070A1 (en) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | BROMODOMINIUM INHIBITORS AND USES OF THE SAME |
WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
TWI602820B (en) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | Bromodomain inhibitors and uses thereof |
WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9969747B2 (en) | 2014-06-20 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide |
WO2023220395A1 (en) * | 2022-05-13 | 2023-11-16 | University Of Cincinnati | Benzodiazepine analogs and methods of use in treating cancer |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH408045A (en) | 1959-12-10 | 1966-02-28 | Hoffmann La Roche | Process for the preparation of benzophenone derivatives |
NL279830A (en) | 1961-06-20 | |||
US3182067A (en) | 1964-04-09 | 1965-05-04 | Hoffmann La Roche | Benzodiazepine compounds |
FR1497456A (en) | 1964-06-15 | 1967-10-13 | Clin Byla Ets | Ortho-amino aryl ketimines, heterocyclic compounds attached to them and preparation of these various bodies |
IL29988A0 (en) | 1967-06-23 | 1968-07-25 | American Cyanamid Co | Novel 7-trifluoromethoxybenzo-1,4-diazepines |
US3631029A (en) | 1967-12-01 | 1971-12-28 | Sumitomo Chemical Co | Process for producing benzodiazepine derivatives |
FR2085645A1 (en) | 1970-04-22 | 1971-12-31 | Chimidrog | 1-phenyl-2,3-benzodiazepin-4-ones - as tranquillizers |
US3801569A (en) | 1973-01-15 | 1974-04-02 | Hoffmann La Roche | 7-(1,1-difluoroalkyl)-1,4-benzodiazepines |
DE3119874A1 (en) | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "BENZAZEPINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS" |
PH26955A (en) | 1989-03-08 | 1992-12-03 | Kali Chemie Pharma Gmbh | Novel 1,7-fused 1H-indole-2-carboxylic acid N-(1,4-benzodiazepin-3-YL) amides |
TW221687B (en) | 1992-01-24 | 1994-03-11 | Hoffmann La Roche | |
DE19604920A1 (en) * | 1996-02-01 | 1997-08-07 | Schering Ag | New 2,3-benzodiazepine derivatives, their production and use as medicines |
US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
WO2000079263A2 (en) | 1999-06-18 | 2000-12-28 | Synt:Em S.A. | Identifying active molecules using physico-chemical parameters |
WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
-
2002
- 2002-06-07 CA CA002446696A patent/CA2446696A1/en not_active Abandoned
- 2002-06-07 WO PCT/FR2002/001952 patent/WO2002098865A2/en active Application Filing
- 2002-06-07 NZ NZ529582A patent/NZ529582A/en unknown
- 2002-06-07 IL IL15910502A patent/IL159105A0/en unknown
- 2002-06-07 US US10/479,000 patent/US7250410B2/en not_active Expired - Fee Related
- 2002-06-07 AU AU2002317910A patent/AU2002317910B2/en not_active Ceased
- 2002-06-07 JP JP2003501989A patent/JP2005503356A/en active Pending
- 2002-06-07 EP EP02747514A patent/EP1392663A2/en not_active Withdrawn
-
2003
- 2003-11-27 IL IL159105A patent/IL159105A/en not_active IP Right Cessation
-
2004
- 2004-01-06 ZA ZA200400057A patent/ZA200400057B/en unknown
-
2008
- 2008-09-18 AU AU2008221554A patent/AU2008221554A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005503356A5 (en) | ||
TW585866B (en) | Novel pyrazolobenzodiazepines and pharmaceutical compositions containing the same | |
CA2446696A1 (en) | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | |
EP1556055B1 (en) | Cyclic nucleotide phosphodiesterase inhibitors having a benzodiazepine structure and their use in therapy | |
JP2007505922A5 (en) | ||
JP2003500392A (en) | Heterocyclic analgesic compounds and methods of use | |
JPH09500397A (en) | Benzodiazepines | |
JP2007538068A (en) | Novel fused heterocycles and their use | |
US6476050B2 (en) | 3-substituted piperidines comprising urea functionality, and methods of use thereof | |
US6635661B2 (en) | Heterocyclic analgesic compounds and methods of use thereof | |
US7129228B2 (en) | Heterocyclic analgesic compounds and methods of use thereof | |
EP1296961B1 (en) | 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists | |
US5254548A (en) | Compounds having an aryltriazine structure | |
CN103946214A (en) | 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors | |
JP3950018B2 (en) | Novel octahydro-2H-pyrido [1,2-a] pyrazine compounds, processes for their preparation and pharmaceutical compositions containing them | |
JPH09502199A (en) | Fused tricyclic heteroaromatic derivatives as dopamine receptor subtype ligands | |
JPH07505382A (en) | Imidazole, triazole and tetrazole derivatives | |
WO1997028157A1 (en) | NOVEL PIPERIDINE DERIVATIVES 4-SUBSTITUTED BY AN IMIDAZOLIDIN-2-ON-1-YL-ETHYL, TETRAHYDROPYRIMIDIN-2-ON-1-YL-ETHYL AND 1,3-DIAZEPIN-2-ON-1-YL-ETHYL GROUP, AND USE THEREOF AS α2-ADRENERGIC RECEPTOR ANTAGONISTS | |
US6476046B1 (en) | Diazabicyclo[4.3.0]nonanes, and methods of use thereof | |
JPH07505649A (en) | Heteroaromatic 5-hydroxytryptamine receptor agonist | |
EP0719264A1 (en) | Imidazolone and oxazolone derivatives as dopamine antagonists | |
ZA200505412B (en) | Cyclic nucleotide phosphodiestierase inhibitors, preperation and uses | |
JP2001516745A (en) | Substituted isoquinolines as anticonvulsants | |
US20080234247A1 (en) | Heterocyclic analgesic compounds and methods of use thereof | |
GB2310376A (en) | Tetrahydropyridine derivatives as dopamine receptor subtype ligands |